Quick Answer
Atara Biotherapeutics, Inc. reported Total Assets of $20.24 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed a decrease of -81.5% in Total Assets from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2014: $54.12 million | Q1 2015: $169.82 million | Q2 2015: $161.10 million | Q3 2015: $340.38 million | Q1 2016: $312.98 million | Q2 2016: $300.81 million | Q3 2016: $284.42 million | Q1 2017: $241.74 million | Q2 2017: $244.16 million | Q3 2017: $229.69 million | Q1 2018: $473.11 million | Q2 2018: $492.71 million | Q3 2018: $442.94 million | Q1 2019: $324.73 million | Q2 2019: $274.14 million | Q3 2019: $364.79 million | Q1 2020: $299.55 million | Q2 2020: $428.11 million | Q3 2020: $405.53 million | Q1 2021: $529.64 million | Q2 2021: $456.79 million | Q3 2021: $449.92 million | Q1 2022: $397.28 million | Q2 2022: $436.12 million | Q3 2022: $368.32 million | Q1 2023: $302.08 million | Q2 2023: $246.44 million | Q3 2023: $188.79 million | Q1 2024: $165.27 million | Q2 2024: $117.28 million | Q3 2024: $142.71 million | Q1 2025: $62.04 million | Q2 2025: $36.90 million | Q3 2025: $30.17 million.
- Over the full 13 years of available data (2013 to 2025), Atara Biotherapeutics, Inc.'s Total Assets has declined by 61.0%.
- Historical annual values: Fiscal year 2025: $20.24 million | Fiscal year 2024: $109.10 million | Fiscal year 2023: $165.50 million | Fiscal year 2022: $376.42 million | Fiscal year 2021: $468.13 million | Fiscal year 2020: $588.12 million | Fiscal year 2019: $342.94 million | Fiscal year 2018: $391.84 million | Fiscal year 2017: $217.78 million | Fiscal year 2016: $263.91 million | Fiscal year 2015: $324.98 million | Fiscal year 2014: $106.12 million | Fiscal year 2013: $51.83 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: